1
|
Takedachi M, Kawasaki K, Sawada K, Sakura K, Murata M, Shimomura J, Kawakami K, Morimoto C, Miki K, Takeshita N, Iwayama T, Okura H, Matsuyama A, Saito M, Kitamura M, Murakami S. Periodontal Tissue Regeneration by Transplantation of Autologous Adipose Tissue-Derived Multi-Lineage Progenitor Cells With Carbonate Apatite. Cell Transplant 2023; 32:9636897231198296. [PMID: 37710973 PMCID: PMC10503283 DOI: 10.1177/09636897231198296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 08/09/2023] [Accepted: 08/15/2023] [Indexed: 09/16/2023] Open
Abstract
We have developed an autologous transplantation method using adipose tissue-derived multi-lineage progenitor cells (ADMPCs) as a method of periodontal tissue regeneration that can be adapted to severe periodontal disease. Our previous clinical study confirmed the safety of autologous transplantation of ADMPCs and demonstrated its usefulness in the treatment of severe periodontal disease. However, in the same clinical study, we found that the fibrin gel used as the scaffold material might have caused gingival recession and impaired tissue regeneration in some patients. Carbonate apatite has a high space-making capacity and has been approved in Japan for periodontal tissue regeneration. In this study, we selected carbonate apatite as a candidate scaffold material for ADMPCs and conducted an in vitro examination of its effect on the cellular function of ADMPCs. We further performed autologous ADMPC transplantation with carbonate apatite as the scaffold material in a model of one-wall bone defects in beagles and then analyzed the effect on periodontal tissue regeneration. The findings showed that carbonate apatite did not affect the cell morphology of ADMPCs and that it promoted proliferation. Moreover, no effect on secretor factor transcription was found. The results of the in vivo analysis confirmed the space-making capacity of carbonate apatite, and the acquisition of significant new attachment was observed in the group involving ADMPC transplantation with carbonate apatite compared with the group involving carbonate apatite application alone. Our results demonstrate the usefulness of carbonate apatite as a scaffold material for ADMPC transplantation.
Collapse
Affiliation(s)
- Masahide Takedachi
- Department of Periodontology and Regenerative Dentistry, Osaka University Graduate School of Dentistry, Suita, Japan
| | - Kohsuke Kawasaki
- Department of Periodontology and Regenerative Dentistry, Osaka University Graduate School of Dentistry, Suita, Japan
| | - Keigo Sawada
- Department of Periodontology and Regenerative Dentistry, Osaka University Graduate School of Dentistry, Suita, Japan
| | - Kazuma Sakura
- Department of Medical Innovation, Osaka University Hospital, Suita, Japan
| | - Mari Murata
- Department of Periodontology and Regenerative Dentistry, Osaka University Graduate School of Dentistry, Suita, Japan
| | - Junpei Shimomura
- Department of Periodontology and Regenerative Dentistry, Osaka University Graduate School of Dentistry, Suita, Japan
| | - Kazuma Kawakami
- Department of Periodontology and Regenerative Dentistry, Osaka University Graduate School of Dentistry, Suita, Japan
| | - Chiaki Morimoto
- Department of Periodontology and Regenerative Dentistry, Osaka University Graduate School of Dentistry, Suita, Japan
| | - Koji Miki
- Department of Periodontology and Regenerative Dentistry, Osaka University Graduate School of Dentistry, Suita, Japan
| | - Noboru Takeshita
- Department of Periodontology and Regenerative Dentistry, Osaka University Graduate School of Dentistry, Suita, Japan
| | - Tomoaki Iwayama
- Department of Periodontology and Regenerative Dentistry, Osaka University Graduate School of Dentistry, Suita, Japan
| | - Hanayuki Okura
- Center for Reverse Translational Research, Osaka Habikino Medical Center, Osaka Prefectural Hospital Organization, Habikino, Japan
- Adipo Medical Technology, Osaka, Japan
- Institute of Innovative Medical Technology, Osaka. Japan
| | - Akifumi Matsuyama
- Center for Reverse Translational Research, Osaka Habikino Medical Center, Osaka Prefectural Hospital Organization, Habikino, Japan
| | - Masahiro Saito
- Department of Restorative Dentistry, Division of Operative Dentistry, Tohoku University Graduate School of Dentistry, Sendai, Japan
| | - Masahiro Kitamura
- Department of Periodontology and Regenerative Dentistry, Osaka University Graduate School of Dentistry, Suita, Japan
| | - Shinya Murakami
- Department of Periodontology and Regenerative Dentistry, Osaka University Graduate School of Dentistry, Suita, Japan
| |
Collapse
|
2
|
Kiyohara E, Tanemura A, Sakura K, Nakajima T, Myoui A, Yamazaki N, Kiyohara Y, Katayama I, Fujimoto M, Kaneda Y. A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma. Cancer Immunol Immunother 2022; 71:2041-2049. [PMID: 34984539 PMCID: PMC9293878 DOI: 10.1007/s00262-021-03122-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Accepted: 11/25/2021] [Indexed: 12/04/2022]
Abstract
Despite recent advance in immunotherapy agents, safe new therapies that enhance the effects of immune checkpoint inhibitors are still required to develop. We previously demonstrated that hemagglutinating virus of Japan-envelope (HVJ-E) induced not only direct tumor cell death but also antitumor immunity through the activation of T and natural killer (NK) cells, thereafter, developed a manufacturing process of HVJ-E (GEN0101) for clinical use. We here performed a phase Ia clinical trial of intratumoral GEN0101 administration in six patients with stage IIIC or IV malignant melanoma. The primary aim was to evaluate the safety and tolerability of GEN0101, and the secondary aim was to examine the objective tumor response. Patients were separated into two groups (n = 3 each) and received a low dose of 30,000 and high dose of 60,000 mNAU of GEN0101. All patients completed a two-week follow-up evaluation without severe adverse events. The overall response rate was 33% (2 of 6), with 2 partial responses in the high-dose group and 2 with stable disease, and 2 with progressive disease in the low-dose group. Local complete or partial responses were observed in 11 of 18 (61%) target lesions. One patient demonstrated shrinkage of lung metastases after the treatment. The activity of NK cells and interferon-γ levels were increased in the circulation, indicating augmentation of antitumor immunity by GEN0101. This trial showed not only the safety and tolerability but also the significant antitumor effect of GEN0101, suggesting that GEN0101 might be a promising new drug for patients with advanced melanoma.
Collapse
|
3
|
Sakura K, Sasai M, Mino T, Uyama H. Non-Woven Sheet Containing Gemcitabine: Controlled Release Complex for Pancreatic Cancer Treatment. Polymers (Basel) 2022; 14:polym14010168. [PMID: 35012190 PMCID: PMC8747259 DOI: 10.3390/polym14010168] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Revised: 12/25/2021] [Accepted: 12/30/2021] [Indexed: 02/04/2023] Open
Abstract
The 5-year survival rate for pancreatic cancer remains low, and the development of new methods for its treatment is actively underway. After the surgical treatment of pancreatic cancer, recurrence and peritoneal dissemination can be prevented by long-term local exposure to appropriate drug concentrations. We propose a novel treatment method using non-woven sheets to achieve this goal. Poly(L-lactic acid) non-woven sheets containing gemcitabine (GEM) were prepared, and GEM sustained release from this delivery system was investigated. Approximately 35% of the GEM dose was released within 30 d. For in vitro evaluation, we conducted a cell growth inhibition test using transwell assays, and significant inhibition of cell growth was observed. The antitumor effects of subcutaneously implanted GEM-containing non-woven sheets were evaluated in mice bearing subcutaneous Panc02 cells, and it was established that the sheets inhibited tumor growth for approximately 28 d. These results suggest the usefulness of GEM-containing non-woven sheets in pancreatic cancer treatment.
Collapse
Affiliation(s)
- Kazuma Sakura
- Respiratory Center, Osaka University Hospital, Osaka 565-0871, Japan
- Department of Surgery, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan
- Division of Translational Research, Osaka University Hospital, Osaka 565-0871, Japan;
- Correspondence: ; Tel.: +81-6-6210-8289
| | - Masao Sasai
- Division of Translational Research, Osaka University Hospital, Osaka 565-0871, Japan;
| | - Takayuki Mino
- Department of Applied Chemistry, Graduate School of Engineering, Osaka University, Osaka 565-0871, Japan; (T.M.); (H.U.)
| | - Hiroshi Uyama
- Department of Applied Chemistry, Graduate School of Engineering, Osaka University, Osaka 565-0871, Japan; (T.M.); (H.U.)
| |
Collapse
|
4
|
Kiyohara E, Tanemura A, Nishioka M, Yamada M, Tanaka A, Yokomi A, Saito A, Sakura K, Nakajima T, Myoui A, Sakurai T, Kawakami Y, Kaneda Y, Katayama I. Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study. Cancer Immunol Immunother 2020; 69:1131-1140. [PMID: 32047956 DOI: 10.1007/s00262-020-02509-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2019] [Accepted: 01/29/2020] [Indexed: 12/19/2022]
Abstract
Hemagglutinating virus of Japan (HVJ; Sendai virus) is an RNA virus that has cell fusion activity. HVJ-envelope (HVJ-E) is a UV-irradiated HVJ particle that loses viral replication and protein synthesis activity but retains cell fusion activity. We recently reported that HVJ-E has antitumor effects on several types of tumors. Here, we describe the results of a first-in-human phase I/IIa study in patients with advanced melanoma, receiving intratumoral administration of HVJ-E. The primary aim was to evaluate the safety and tolerability of HVJ-E, and the secondary aim was to examine the objective tumor response and antitumor immunity. Six patients with stage IIIC or IV progressive malignant melanoma with skin or lymph metastasis were enrolled. Patients were separated into two groups (n = 3 each) and received low and high doses of HVJ-E. Five of the six patients completed 4 weeks of follow-up evaluation; one patient discontinued treatment owing to progressive disease. Complete or partial responses were observed in 3 of 6 (50%) injected target lesions, 7 of 15 (47%) noninjected target lesions, and 10 of 21 (48%) target lesions. Induction of antitumor immunity was observed: activation of natural killer cells, a marked increase in interferon-γ levels in the peripheral blood, and infiltration of cytotoxic T cells into both injected and noninjected tumor lesions. Thus, intratumoral injection of HVJ-E in advanced melanoma patients showed safety and tolerability with local regression of the tumor mediated by antitumor immunity. The results suggest that HVJ-E might be a new treatment approach in patients with advanced melanoma.
Collapse
Affiliation(s)
- Eiji Kiyohara
- Department of Dermatology, Course of Integrated Medicine Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita-shi, Osaka, 565-0871, Japan
| | - Atsushi Tanemura
- Department of Dermatology, Course of Integrated Medicine Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita-shi, Osaka, 565-0871, Japan.
| | - Megumi Nishioka
- Department of Dermatology, Course of Integrated Medicine Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita-shi, Osaka, 565-0871, Japan
| | - Mizuho Yamada
- Department of Dermatology, Course of Integrated Medicine Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita-shi, Osaka, 565-0871, Japan
| | - Aya Tanaka
- Department of Dermatology, Course of Integrated Medicine Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita-shi, Osaka, 565-0871, Japan
| | - Akinori Yokomi
- Department of Dermatology, Course of Integrated Medicine Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita-shi, Osaka, 565-0871, Japan
| | - Atsuhiro Saito
- Medical Center for Translational Research, Osaka University Hospital, 2-2, Yamadaoka, Suita-shi, Osaka, 565-0871, Japan
| | - Kazuma Sakura
- Medical Center for Translational Research, Osaka University Hospital, 2-2, Yamadaoka, Suita-shi, Osaka, 565-0871, Japan
| | | | - Akira Myoui
- Medical Center for Translational Research, Osaka University Hospital, 2-2, Yamadaoka, Suita-shi, Osaka, 565-0871, Japan
| | - Toshiharu Sakurai
- Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8583, Japan
| | - Yutaka Kawakami
- Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8583, Japan
| | - Yasufumi Kaneda
- Division of Gene Therapy Science, Department of Genome Biology, Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita-shi, Osaka, 565-0871, Japan
| | - Ichiro Katayama
- Department of Dermatology, Course of Integrated Medicine Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita-shi, Osaka, 565-0871, Japan
| |
Collapse
|
5
|
Niiyama E, Uto K, Lee CM, Sakura K, Ebara M. Smart Anticancer Nanofibers: Hyperthermia Nanofiber Platform Synergized by Sustained Release of Paclitaxel to Improve Antitumor Efficiency (Adv. Healthcare Mater. 13/2019). Adv Healthc Mater 2019. [DOI: 10.1002/adhm.201970050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Eri Niiyama
- International Center for Materials Nanoarchitectonics (WPI‐MANA)National Institute for Materials Science (NIMS) 1‐1 Namiki Tsukuba Ibaraki 305‐0044 Japan
- Graduate School of Pure and Applied SciencesUniversity of Tsukuba 1‐1‐1 Tennodai Tsukuba Ibaraki 305‐8577 Japan
| | - Koichiro Uto
- International Center for Young Scientists (ICYS)National Institute for Materials Science (NIMS) 1‐1 Namiki Tsukuba Ibaraki 305‐0044 Japan
| | - Chun Man Lee
- Medical Center for Translational ResearchOsaka University Hospital 2‐2 Yamadaoka Suita Osaka 565‐0871 Japan
| | - Kazuma Sakura
- Medical Center for Translational ResearchOsaka University Hospital 2‐2 Yamadaoka Suita Osaka 565‐0871 Japan
| | - Mitsuhiro Ebara
- International Center for Materials Nanoarchitectonics (WPI‐MANA)National Institute for Materials Science (NIMS) 1‐1 Namiki Tsukuba Ibaraki 305‐0044 Japan
- Graduate School of Pure and Applied SciencesUniversity of Tsukuba 1‐1‐1 Tennodai Tsukuba Ibaraki 305‐8577 Japan
- Graduate School of Industrial Science and TechnologyTokyo University of Science 6‐3‐1 Niijuku, Katsushika‐ku Tokyo 125‐8585 Japan
| |
Collapse
|
6
|
Niiyama E, Uto K, Lee CM, Sakura K, Ebara M. Hyperthermia Nanofiber Platform Synergized by Sustained Release of Paclitaxel to Improve Antitumor Efficiency. Adv Healthc Mater 2019; 8:e1900102. [PMID: 31091019 DOI: 10.1002/adhm.201900102] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Revised: 04/27/2019] [Indexed: 12/24/2022]
Abstract
Effective cancer therapy can be achieved by designing a smart nanofiber system with the combination of chemotherapy and hyperthermia. This study demonstrates the in vivo antitumor effect of a nanofiber mesh that can deliver heat and antitumor drug in a controlled manner. The mesh is composed of biodegradable poly(ε-caprolactone) (PCL) with paclitaxel (PTX) and magnetic nanoparticles (MNPs). The PCL mesh releases PTX slowly for at least 6 weeks when tested in vitro. The prolonged therapeutic effect is observed in vivo as a continuous release of medication from the mesh over an extended period of time compared with direct injection of PTX into the tumor site. In addition, the synergistic anticancer effect is achieved upon excitation of the mesh with an alternating magnetic field because the MNPs within the nanofiber generate localized heat which causes heat-induced cell killing as well as enhanced chemotherapeutic effect of PTX. Based on these results, the smart nanofiber system may be very promising for cancer therapeutics in the future and may provide knowledge for new development of localized drug delivery.
Collapse
Affiliation(s)
- Eri Niiyama
- International Center for Materials Nanoarchitectonics (WPI‐MANA)National Institute for Materials Science (NIMS) 1‐1 Namiki Tsukuba Ibaraki 305‐0044 Japan
- Graduate School of Pure and Applied SciencesUniversity of Tsukuba 1‐1‐1 Tennodai Tsukuba Ibaraki 305‐8577 Japan
| | - Koichiro Uto
- International Center for Young Scientists (ICYS)National Institute for Materials Science (NIMS) 1‐1 Namiki Tsukuba Ibaraki 305‐0044 Japan
| | - Chun Man Lee
- Medical Center for Translational ResearchOsaka University Hospital 2‐2 Yamadaoka Suita Osaka 565‐0871 Japan
| | - Kazuma Sakura
- Medical Center for Translational ResearchOsaka University Hospital 2‐2 Yamadaoka Suita Osaka 565‐0871 Japan
| | - Mitsuhiro Ebara
- International Center for Materials Nanoarchitectonics (WPI‐MANA)National Institute for Materials Science (NIMS) 1‐1 Namiki Tsukuba Ibaraki 305‐0044 Japan
- Graduate School of Pure and Applied SciencesUniversity of Tsukuba 1‐1‐1 Tennodai Tsukuba Ibaraki 305‐8577 Japan
- Graduate School of Industrial Science and TechnologyTokyo University of Science 6‐3‐1 Niijuku, Katsushika‐ku Tokyo 125‐8585 Japan
| |
Collapse
|
7
|
Yoneoka S, Nakagawa Y, Uto K, Sakura K, Tsukahara T, Ebara M. Boron-incorporating hemagglutinating virus of Japan envelope (HVJ-E) nanomaterial in boron neutron capture therapy. Sci Technol Adv Mater 2019; 20:291-304. [PMID: 30956733 PMCID: PMC6442114 DOI: 10.1080/14686996.2019.1586051] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/01/2018] [Revised: 02/19/2019] [Accepted: 02/19/2019] [Indexed: 06/09/2023]
Abstract
Combining immunotherapeutic and radiotherapeutic technique has recently attracted much attention for advancing cancer treatment. If boron-incorporated hemagglutinating virus of Japan-envelope (HVJ-E) having high membrane fusion ability can be used as a boron delivery agent in boron neutron capture therapy (BNCT), a radical synergistic improvement of boron accumulation efficiency into tumor cells and antitumor immunity may be induced. In this study, we aimed to develop novel boron-containing biocompatible polymers modified onto HVJ-E surfaces. The copolymer consisting of 2-methacryloyloxyethyl phosphorylcholine (MPC) and methacrylamide benzoxaborole (MAAmBO), poly[MPC-co-MAAmBO], was successfully synthesized by using a simple free radical polymerization. The molecular structures and molecular weight of the poly[MPC-co-MAAmBO] copolymer were characterized by nuclear magnetic resonance and matrix-assisted laser desorption ionization time-of-flight mass spectrometry, respectively. The poly[MPC-co-MAAmBO] was coated onto the HVJ-E surface via the chemical bonding between the MAAmBO moiety and the sugar moiety of HVJ-E. DLS, AFM, UV-Vis, and fluorescence measurements clarified that the size of the poly[MPC-co-MAAmBO]-coated HVJ-E, HVJ-E/p[MPC-MAAmBO], to be about 130 ~ 150 nm in diameter, and that the polymer having 9.82 × 106 ~ 7 boron atoms was steadily coated on a single HVJ-E particle. Moreover, cellular uptake of poly[MPC-co-MAAmBO] could be demonstrated without cytotoxicity, and the hemolysis could be successfully suppressed by 20%. These results indicate that the HVJ-E/p[MPC-MAAmBO] may be used as boron nanocarriers in a combination of immunotherapy with BNCT.
Collapse
Affiliation(s)
- Shuichiro Yoneoka
- Laboratory for Advanced Nuclear Energy, Tokyo Institute of Technology, Tokyo, Japan
| | - Yasuhiro Nakagawa
- International Center for Materials Nanoarchitectonics (WPI-MANA), National Institute for Materials Science (NIMS), Tsukuba, Ibaraki, Japan
- Graduate School of Pure and Applied Science, University of Tsukuba, Tsukuba, Ibaraki, Japan
- Graduate School of Engineering, The University of Tokyo, Tokyo, Japan
- Innovation Center of NanoMedicine, Kawasaki Institute of Industrial Promotion, Kawasaki-ku, Kawasaki, Japan
| | - Koichiro Uto
- International Center for Materials Nanoarchitectonics (WPI-MANA), National Institute for Materials Science (NIMS), Tsukuba, Ibaraki, Japan
| | - Kazuma Sakura
- Department of Medical Innovation, and Respiratory Center, Osaka University Hospital, Suita, Osaka, Japan
| | - Takehiko Tsukahara
- Laboratory for Advanced Nuclear Energy, Tokyo Institute of Technology, Tokyo, Japan
| | - Mitsuhiro Ebara
- International Center for Materials Nanoarchitectonics (WPI-MANA), National Institute for Materials Science (NIMS), Tsukuba, Ibaraki, Japan
- Graduate School of Pure and Applied Science, University of Tsukuba, Tsukuba, Ibaraki, Japan
- Graduate School of Industrial Science and Technology, Tokyo University of Science, Katsushika-ku, Tokyo, Japan
| |
Collapse
|
8
|
Sakura K, Lee C, Kaneda Y, Nakano T, Atagi S, Kadota Y, Kuribayashi K, Kuroyama M, Kijima T, Kumanogoh A, Okumura M. P1.14-19 Hemagglutinating Virus of Japan Envelope (HVJ-E: Inactivated Viral Nanoparticles) Against Chemotherapy-Resistant Pleural Mesothelioma. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.921] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
9
|
Niiyama E, Uto K, Lee CM, Sakura K, Ebara M. Alternating Magnetic Field-Triggered Switchable Nanofiber Mesh for Cancer Thermo-Chemotherapy. Polymers (Basel) 2018; 10:polym10091018. [PMID: 30960944 PMCID: PMC6404069 DOI: 10.3390/polym10091018] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Revised: 09/04/2018] [Accepted: 09/12/2018] [Indexed: 11/16/2022] Open
Abstract
We have developed a smart anti-cancer fiber mesh that is able to control tumor-killing activity against lung adenocarcinoma precisely. The mesh is capable of carrying large loads of chemotherapeutic drug, paclitaxel (PTX), as well as magnetic nanoparticles (MNPs). The mesh generates heat when the loaded MNPs are activated in an alternating magnetic field (AMF). The mesh is thermo-responsive, so the heat generated can be also used to trigger PTX release from the mesh. An electrospinning method was employed to fabricate the mesh using a copolymer of N-isopropylacrylamide and N-hydroxymethylacrylamide, the phase transition temperature of which was adjusted to the mild-hyperthermia temperature range around 43 °C. In vitro anti-tumor studies demonstrated that both MNP- and PTX-loaded mesh killed about 66% of cells, whereas only PTX-loaded mesh killed about 43% of cells. In a mouse lung cancer model, the thermo-chemotherapy combo displayed enhanced anti-tumor activity and the systemic toxic effects on mice were eliminated due to local release of the chemotherapeutic agents. The proposed fiber system might provide a blueprint to guide the design of the next generation of local drug delivery systems for safe and effective cancer treatment.
Collapse
Affiliation(s)
- Eri Niiyama
- International Center for Materials Nanoarchitectonics (WPI-MANA), National Institute for Materials Science (NIMS), Tsukuba, Ibaraki 305-0044, Japan.
- Graduate School of Pure and Applied Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan.
| | - Koichiro Uto
- International Center for Young Scientists (ICYS), National Institute for Materials Science (NIMS), Tsukuba, Ibaraki 305-0044, Japan.
| | - Chun Man Lee
- Medical Center for Translational Research, Osaka University Hospital, Suita, Osaka 565-0871, Japan.
| | - Kazuma Sakura
- Medical Center for Translational Research, Osaka University Hospital, Suita, Osaka 565-0871, Japan.
| | - Mitsuhiro Ebara
- International Center for Materials Nanoarchitectonics (WPI-MANA), National Institute for Materials Science (NIMS), Tsukuba, Ibaraki 305-0044, Japan.
- Graduate School of Pure and Applied Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8577, Japan.
- Graduate School of Industrial Science and Technology, Tokyo University of Science, Katsushika-ku, Tokyo 125-8585, Japan.
| |
Collapse
|
10
|
Yuda I, Sakura K, Narahashi S, Morita K. [A fundamental study of the Amerlex Digoxin RIA kit (author's transl)]. Radioisotopes 1982; 31:202-4. [PMID: 7111774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|